NASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis $144.46 -2.08 (-1.42%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Repligen Stock (NASDAQ:RGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Repligen alerts:Sign Up Key Stats Today's Range$143.96▼$150.5650-Day Range$123.41▼$160.9252-Week Range$113.50▼$211.13Volume1.57 million shsAverage Volume658,638 shsMarket Capitalization$8.09 billionP/E RatioN/ADividend YieldN/APrice Target$185.20Consensus RatingModerate Buy Company OverviewRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More… Repligen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks82nd Percentile Overall ScoreRGEN MarketRank™: Repligen scored higher than 82% of companies evaluated by MarketBeat, and ranked 181st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageRepligen has only been the subject of 4 research reports in the past 90 days.Read more about Repligen's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.04% Earnings GrowthEarnings for Repligen are expected to grow by 11.04% in the coming year, from $1.54 to $1.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is -390.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is -390.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioRepligen has a PEG Ratio of 4.64. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.34% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Repligen has recently decreased by 3.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.33 Percentage of Shares Shorted6.34% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Repligen has recently decreased by 3.79%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment0.51 News SentimentRepligen has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Repligen this week, compared to 7 articles on an average week.Search InterestOnly 4 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repligen's insider trading history. Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Stock News HeadlinesRepligen (NASDAQ:RGEN) Stock Rating Lowered by StockNews.comDecember 21 at 3:29 AM | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Receives $185.20 Consensus Price Target from BrokeragesDecember 21 at 1:55 AM | americanbankingnews.comHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 22, 2024 | Porter & Company (Ad)Repligen Corporation (RGEN) Fell Along with PeersDecember 20 at 10:38 AM | insidermonkey.comRepligen (NASDAQ:RGEN) Now Covered by Analysts at Canaccord Genuity GroupDecember 20 at 3:23 AM | americanbankingnews.comBioLife Solutions appoints Hunt to board of directorsDecember 17, 2024 | markets.businessinsider.comRepligen initiated with a Hold at CanaccordDecember 17, 2024 | markets.businessinsider.comBioLife Solutions Appoints Tony J. Hunt to its Board of DirectorsDecember 16, 2024 | prnewswire.comSee More Headlines RGEN Stock Analysis - Frequently Asked Questions How have RGEN shares performed this year? Repligen's stock was trading at $179.80 on January 1st, 2024. Since then, RGEN shares have decreased by 19.7% and is now trading at $144.46. View the best growth stocks for 2024 here. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) posted its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. Does Repligen have any subsidiaries? Repligen subsidiaries include ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and more. Who are Repligen's major shareholders? Top institutional shareholders of Repligen include State Street Corp (2.90%), Champlain Investment Partners LLC (2.54%), Brown Capital Management LLC (2.00%) and Impax Asset Management Group plc (1.89%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus, Manner Carrie Eglinton and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/12/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,783Year Founded1981Price Target and Rating Average Stock Price Target$185.20 High Stock Price Target$220.00 Low Stock Price Target$155.00 Potential Upside/Downside+28.2%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E Ratio93.81 P/E Growth4.64Net Income$35.60 million Net Margins-3.36% Pretax Margin2.18% Return on Equity3.90% Return on Assets2.72% Debt Debt-to-Equity Ratio0.26 Current Ratio10.44 Quick Ratio8.76 Sales & Book Value Annual Sales$639.92 million Price / Sales12.65 Cash Flow$2.80 per share Price / Cash Flow51.55 Book Value$35.19 per share Price / Book4.11Miscellaneous Outstanding Shares56,027,000Free Float55,355,000Market Cap$8.09 billion OptionableOptionable Beta0.96 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:RGEN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.